Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
Publication
, Journal Article
Farnier, M; Gaudet, D; Valcheva, V; Minini, P; Miller, K; Cariou, B
Published in: International Journal of Cardiology
November 2016
Duke Scholars
Published In
International Journal of Cardiology
DOI
ISSN
0167-5273
Publication Date
November 2016
Volume
223
Start / End Page
750 / 757
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Farnier, M., Gaudet, D., Valcheva, V., Minini, P., Miller, K., & Cariou, B. (2016). Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. International Journal of Cardiology, 223, 750–757. https://doi.org/10.1016/j.ijcard.2016.08.273
Farnier, Michel, Daniel Gaudet, Velichka Valcheva, Pascal Minini, Kathryn Miller, and Bertrand Cariou. “Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials.” International Journal of Cardiology 223 (November 2016): 750–57. https://doi.org/10.1016/j.ijcard.2016.08.273.
Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. International Journal of Cardiology. 2016 Nov;223:750–7.
Farnier, Michel, et al. “Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials.” International Journal of Cardiology, vol. 223, Elsevier BV, Nov. 2016, pp. 750–57. Crossref, doi:10.1016/j.ijcard.2016.08.273.
Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. International Journal of Cardiology. Elsevier BV; 2016 Nov;223:750–757.
Published In
International Journal of Cardiology
DOI
ISSN
0167-5273
Publication Date
November 2016
Volume
223
Start / End Page
750 / 757
Publisher
Elsevier BV
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology